Experience of sentinel node biopsy alone in early breast cancer without further axillary dissection in patients with negative sentinel node

ANZ Journal of Surgery

Volumn 75, Issue 5, 2005, Pages 292-299

  Soni, Naresh K ^a   Spillane, Andrew J ^a,b,c  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b Mater Hospital   (Australia)

^c PRINCE OF WALES PRIVATE HOSPITAL   (Australia)

Author keywords

Axillary staging; Early breast cancer; Lymphatic metastasis; Sentinel lymph node biopsy

Indexed keywords

ACCURACY; ADULT; ARTICLE; AUSTRALIA; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CONTROL; CANCER RECURRENCE; CANCER STAGING; EARLY CANCER; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHOSCINTIGRAPHY; MAJOR CLINICAL STUDY; MORBIDITY; PROGNOSIS; RELIABILITY; RETROSPECTIVE STUDY; SENTINEL LYMPH NODE BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; AXILLA; BREAST NEOPLASMS; FALSE NEGATIVE REACTIONS; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY;

EID: 20444491237     PISSN: 14451433     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-2197.2005.03376.x     Document Type: Article

References (82)

1. Carter CL, Allen C, Henson DE. Relation of tumour size, lymph nodes status and survival in 24 740 breast cancer cases. Cancer 1989; 63: 181-7.
2. Fisher ER, Anderson S, Redmond C, Fisher B. Pathologic findings from the National Surgical Adjuvant Breast Project Protocol B-06: 10 year pathological and clinical prognostic discriminants. Cancer 1993; 71: 2507-14.
3. Spillane AJ, Sacks NPM. Role of axillary surgery in early breast cancer: review of the current evidence. ANZ J. Surg. 2000; 70: 515-24.
4. Kelley MC, Giuliano AE. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. In: Bland KI, Copeland EM III (eds) The Breast: Comprehensive Management of Benign and Malignant Diseases, 2nd edn. Philadelphia: W.B. Saunders Company, 1998; Ch. 56.
5. Taylor KO. Morbidity associated with axillary surgery for breast cancer. ANZ J. Surg. 2004; 74: 314-17.
6. Ververs JM, Roumen RM, Vingerhoets AJ et al. Risk, severity and predictors of physical and psychological morbidity after axillary lymph node dissection for breast cancer. Eur. J. Cancer 2001; 37: 991-9.
7. Lin PP, Allison DC, Wainstock J et al. Impact of axillary dissection on the therapy of the breast cancer patients. J. Clin. Oncol. 1993; 11: 1536-44.
8. Cady B, Stone MD, Schuler JG, Thakur R, Wanner MA, Lavin PT. The new era in breast cancer: invasion, size and nodal involvement dramatically decreasing as a result of mammographic screening. Arch. Surg. 1996; 131: 301-8.
9. Chua B, Ung O, Taylor R, Bilous M, Salisbury E, Boyages J. Treatment implications of a positive sentinel lymph node biopsy for patients with early breast carcinoma. Cancer 2001; 92: 1769-74.
10. Mignotte H, Treilleux I, Faure C, Nessah K, Bremond A. Axillary lymph-node dissection for positive sentinel nodes in breast cancer patients. Eur. J. Surg. Oncol. 2002; 28: 623-6.
11. Veronesi U, Rilike F, Luini A et al. Distribution of axillary node metastases by level of invasion. An analysis of 539 cases. Cancer 1987; 59: 682-7.
12. Albertini JJ, Lyman GH, Cox C et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996; 276: 1818-22.
13. Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg. Oncol. 1993; 2: 335-40.
14. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann. Surg. 1994; 220: 391-401.
15. Giuliano AE, Haigh PI, Brennan MB et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J. Clin. Oncol. 2000; 18: 2553-9.
16. Schrenk P, Hatzl-Griesenhofer M, Shamiyeh A, Waynad W. Follow-up of sentinel node negative breast cancer patients without axillary lymph node dissection. J. Surg. Oncol. 2001; 77: 165-70.
17. Travagli JP, Atallah D, Mathieu MC et al. Sentinel lymphadenectomy without systemic axillary dissection in breast cancer patients: predictors of non-sentinel lymph node metastasis. Eur. J. Surg. Oncol. 2003; 29: 403-6.
18. Reitsamer R, Peintinger F, Prokop E, Menzel C, Cimpoca W, Rettenbacher L. Sentinel lymph node biopsy alone without axillary lymph node dissection - follow up of sentinel lymph node negative breast cancer patients. Eur. J. Surg. Oncol. 2003; 29: 221-3.
19. Gill PG. Sentinel lymph node biopsy versus axillary clearance in operable breast cancer. The RACS SNAC Trial, a multicenter randomized trial of the Royal Australian College of Surgeons (RACS) section of breast surgery, in collaboration with the National Health and Medical Research Council Clinical Trials Center. Ann. Surg. Oncol. 2004; 11: 216S-21S.
20. Clarke D, Khonji NI, Mansel RE. Sentinel Node Biopsy in Breast Cancer: ALMANAC Trial. World J. Surg. 2001; 25: 819-22.
21. Krag DN, Julian TB, Harlow SP et al. NSABP-32: Phase III, randomized trial comparing axillary resection with sentinel lymph node dissection: a description of the trial. Ann. Surg. Oncol. 2004; 11: 208S-10S.
22. Spillane A. Sentinel node biopsy in breast cancer and melanoma requires adequate self-audit. ANZ J. Surg. 2004; 74: 308-13.
23. Greene FL, Page DL, Fleming ID et al. AJCC Staging Manual, 6th edn. New York: Springer-Verlag, 2002.
24. Martin RC, Edwards MJ, Wong SL et al. Practical guidelines for optimal gamma probe detection of sentinel lymph nodes in breast cancer: results of a multi-institutional study. For the University of Louisville Breast Cancer Study Group. Surgery 2000; 128: 139-44.
25. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer: experience from a long study with long-term follow-up. Histopathology 1991; 19: 403-10.
26. National Institutes of Health. NIH consensus conference on the treatment of early-stage breast cancer. JAMA 1991; 265: 391-5.
27. Saiz E, Toonkel R, Poppiti RJ, Robinson MJ. Infiltrating breast carcinoma smaller than 0.5 centimeters: is lymph node dissection necessary? Cancer 1999; 85: 2206-11.
28. Maibenco DC, Weiss LK, Pawlish KS, Severson RK. Axillary lymph node metastases associated with small invasive breast carcinomas. Cancer 1999; 85: 1530-6.
29. Veronesi U, Paganelli G, Viale G et al. Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J. Natl. Cancer Inst. 1999; 91: 368-73.
30. Kollias J, Gill PG, Chatterton BE et al. Reliability of sentinel node status in predicting axillary lymph node involvement in breast cancer. Med. J. Aust. 1999; 171: 461-5.
31. Molland JG, Dias MM, Gillett DJ. Sentinel node biopsy in breast cancer. Results of 103 cases. ANZ J. Surg. 2000; 70: 98-102.
32. Gemignani ML, Cody HS, Fey JV, Tran KN, Venkatraman E, Borgen PI. Impact of sentinel lymph node mapping on relative charges in patients with early breast cancer. Ann. Surg. Oncol. 2000; 7: 575-80.
33. Veronesi U, Paganelli G, Viale G et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N. Engl. J. Med. 2003; 349: 546-53.
34. Mansel RE, Goyal A, Fallowfield L, Newcombe RG. Sentinel node biopsy in breast cancer: the first results of the randomized multicenter ALMANAC trial. Paper Presented at: 2004 American Society of Clinical Oncology ASCO Annual Meeting. [Cited 4 August 2004]. Abstract no. 506 available from URL: http://www.asco.org/ac/1,1003,_12-002643-00_ 18-0026-00_19-002018,00.asp.
35. Veronesi U, Paganelli G, Galimberti V et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 1997; 349: 1864-7.
36. Yong WS, Wong CY, Lee JSY, Soo KC, Tan PH, Goh ASW. Single institution's initial experience with sentinel lymph node biopsy in breast cancer patients. ANZ J. Surg. 2003; 73: 416-21.
37. Cody HS III. Sentinel lymph node biopsy for breast cancer: Does anybody not need one? Ann. Surg. Oncol. 2003; 10: 1131-2.
38. McMasters KM, Wong SL, Chao C et al. Defining the optimal surgeon experience for breast cancer sentinel lymph node biopsy: a model for implementation of new surgical techniques. Ann. Surg. 2001; 234: 299-300.
39. De Cicco C, Cremonesi M, Luini A et al. Lymphoscintigraphy and radioguided biopsy of the sentinel axillary node in breast cancer. J. Nucl. Med. 1998; 12: 2080-4.
40. Wong SL, Edwards MJ, Chao C et al. The effect of prior breast biopsy method and concurrent definitive breast procedure on success and accuracy of sentinel lymph node biopsy. Ann. Surg. Oncol. 2002; 9: 272-7.
41. Haigh PI, Hansen NM, Qi K, Giuliano AE. Biopsy method and excision volume do not affect success rate of subsequent sentinel lymph node dissection in breast cancer. Ann. Surg. Oncol. 2000; 7: 21-7.
42. Bonadonna G, Valagussa P, Brambilla C et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J. Clin. Oncol. 1998; 16: 93-100.
43. Fisher B, Brown A, Mamounas E et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project B-18. J. Clin. Oncol. 1997; 15: 2483-93.
44. Rubens RD. The management of locally advanced breast cancer. Br. J. Cancer 1992; 65: 145-7.
45. Meric F, Mirza NQ, Buzdar AU et al. Prognostic implications of pathological lymph node status after preoperative chemotherapy for operable T3N0M0 breast cancer. Ann. Surg. Oncol. 2000; 7: 435-40.
46. Bedrosian I, Reynolds C, Mick R et al. Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors. Cancer 2000; 88: 2540-5.
47. Chung MH, Ye W, Giuliano AE. Role for sentinel lymph node dissection in the management of large (≤5 cm) invasive breast cancer. Ann. Surg. Oncol. 2001; 8: 688-92.
48. Tousimis E, Van Zee KJ, Fey JV et al. The accuracy of sentinel lymph node biopsy in multicentric and multifocal breast cancers. J. Am. Coll. Surg. 2003; 197: 529-35.
49. Balch GC, Mithani SK, Richards KR, Beauchamp D, Kelly MC. Lymphatic mapping and sentinel lymphadenectomy after preoperative therapy for stage II and III breast cancer. Ann. Surg. Oncol. 2003; 10: 616-21.
50. Stearns V, Ewing CA, Slack R, Penannen MF, Hayes DF, Tsangaris TN. Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann. Surg. Oncol. 2002; 9: 235-42.
51. Port ER, Fey J, Gemignani ML et al. Reoperative sentinel lymph node biopsy: a new option for patients with primary or locally recurrent breast carcinoma. J. Am. Coll. Surg. 2002; 195: 167-72.
52. Nwariku FE, Euhus DM, Beitsch PD et al. Sentinel lymph node biopsy, an alternative to elective axillary dissection for breast cancer. Am. J. Surg. 1998; 176: 529-31.
53. Kollias J, Gill PG, Chatterton B, Raymond W, Collins PJ. Sentinel node biopsy in breast cancer: recommendations for surgeons, pathologists, nuclear physicians and radiologists in Australia and New Zealand. ANZ J. Surg. 2000; 70: 132-6.
54. Schwarte GF, Giuliano AE, Veronesi U, Consensus Conference Committee. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19-22, 2001, Philadelphia, Pennsylvania. Cancer 2002; 94: 2542-52.
55. Clarke D, Newcombe RG, Mansel RE. The learning curve in sentinel node biopsy: the ALMANAC experience. Ann. Surg. Oncol. 2004; 11: 2118-2158.
56. Wong SL, Edwards MJ, Chao C et al. Sentinel lymph node biopsy for breast cancer: impact of the number of sentinel nodes removed on the false-negative rate. J. Am. Coll. Surg. 2001; 192: 684-91.
57. Leidenius M, Krogerus L, Toivonen T, Leppanen E, von Smitten K. The sensitivity of axillary staging when using sentinel node biopsy in breast cancer. Eur. J. Surg. Oncol. 2003; 29: 849-53.
58. Menes TS, Tartter PI, Mizrachi H, Smith SR, Estabrook A. Touch preparation or frozen section for intraoperative detection of sentinel lymph node metastases from breast cancer. Ann. Surg. Oncol. 2003; 10: 1166-70.
59. Kane JM, Edge SB, Winston JS, Watroba N, Kurd TC. Intraoperative pathologic evaluation of a breast cancer sentinel lymph node biopsy as a determinant for synchronous axillary lymph node dissection. Ann. Surg. Oncol. 2001; 8: 361-7.
60. Kamath VJ, Giuliano R, Dauway EL et al. Characteristics of the sentinel lymph node in breast cancer predict further involvement of higher-echelon nodes in the axilla: a study to evaluate the need for complete axillary lymph node dissection. Arch. Surg. 2001; 136: 688-92.
61. Liang WC, Sickle-Santanello BJ, Nims TA. Is complete axillary dissection indicated for micrqrhetastases in the sentinel lymph node? Am. J. Surg. 2001; 182: 365-8.
62. Singletary ES, Alfred C, Ashley P et al. Revision of the American Joint Committee on Cancer Staging System for Breast Cancer. J. Clin. Oncol. 2002; 20: 3628-36.
63. Giuliano A (Study Chair). American College of Surgeons Oncology Group. ACSOG-Z0011. A Randomized Trial of Axillary Node Dissection in Women with Clinical T1-2, N0M0 Breast Cancer Who Have a Positive Sentinel Node. Amendment #6, Revision #1. [Cited 4 August 2004]. Available from URL: http:// www.acosog.org/studies/organ_site/breast/index.jsp
64. Galimberti V (Protocol chair). International Breast Cancer Study Group. IBCSG-Trial-23-01. Phase 111 Randomized Study of Surgical Resection with or Without Axillary Lymph Node Dissection in Women with Clinically Node-Negative Breast Cancer with Sentinel Node Micrometastases. [Cited 4 August 2004]. Available from URL: http://cancer.gov/clinicaltrials/IBCSG-23-01
65. Van Zee KJ, Manasseh D-M E, Bevilacqua JLB et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann. Surg. Oncol. 2003; 10: 1140-51.
66. Cody HS, Klauber-DeMore N, Borgen PI, Van Zee KJ. Is it really duct carcinoma in situ? Ann. Surg. Oncol. 2001; 8: 617-19.
67. Lagios MD, Silverstein MJ. Sentinel node biopsy for patients with DCIS: a dangerous and unwarranted direction. Ann. Surg. Oncol. 2001; 8: 275-7.
68. National Breast Cancer Centre. The Clinical Management of Ductal Carcinoma in Situ, Lobular Carcinoma in Situ and Atypical Hyperplasia of the Breast, 1st edn. Camperdown, NSW: National Breast Cancer Centre, 2003.
69. Silverstein MJ, Rosser RJ, Gierson ED et al. Axillary lymph node dissection for intraductal breast carcinoma - is it indicated? Cancer 1987; 59: 1819-24.
70. Klauber-DeMore N, Lee K, Tan LK, Liberman L et al. Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma in-situ and ductal carcinoma in-situ with microinvasion? Ann. Surg. Oncol. 2000; 7: 636-42.
71. Intra M, Zurrida S, Maffini F et al. Sentinel lymph node metastasis in microinvasive breast cancer. Ann. Surg. Oncol. 2003; 10: 1160-5.
72. Fisher ER, Costantino J, Fisher B, Palekar AS, Redmond C, Mamounas E. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Intraductal carcinoma (ductal carcinoma in situ). The National Surgical Adjuvant Breast and Bowel Project Collaborating Investigators. Cancer 1995; 75: 1310-19.
73. Bijker N, Peterse JL, Duchateau L et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J. Clin. Oncol. 2001; 19: 2263-71.
74. Wong SL, Chao C, Edwards MJ et al. Frequency of sentinel lymph node metastases in patients with favourable breast cancer histologic subtypes. Am. J. Surg. 2002; 184: 492-8.
75. Shen P, Glass EC, DiFronzo LA, Giuliano AE. Dermal versus intraparenchymal lymphoscintigraphy of the breast. Ann. Surg. Oncol. 2001; 8: 241-8.
76. Galimberti V, Veronesi P, Arnone P et al. Stage migration after biopsy of internal mammary chain lymph nodes in breast cancer patients. Ann. Surg. Oncol. 2002; 9: 924-8.
77. Estourgie SH, Nieweg OE, Olmos RA, Rutgers EJ, Kroon BB. Lymphatic drainage patterns from the breast. Ann. Surg. 2004; 239: 232-7.
78. Fleming ID, Cooper JS, Henson DE et al. AJCC Cancer Staging Manual, 5th edn. Philadelphia: Lippincott-Raven, 1997.
79. Nario MT, Kollias J, Farshid G, Gill PG, Bochner M. Clinical impact of false-negative sentinel node biopsy in primary breast cancer. Br. J. Surg. 2002; 89: 1430-4.
80. Chung MA, Steinhoff MM, Cady B. Clinical axillary recurrence in breast cancer patients after a negative sentinel node biopsy. Am. J. Surg. 2002; 184: 310-14.
81. Haid A, Kuehn T, Konstantiniuk P et al. Shoulder-arm morbidity following axillary dissection and sentinel node biopsy for breast cancer. Eur. J. Surg. Oncol. 2002; 28: 705-10.
82. Sener SF, Winchester DJ, Martz CH et al. Lymphedema after sentinel lymphadenectomy for breast carcinoma. Cancer 2001; 92: 748-52.